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Background: The emergence and spread of Plasmodium falciparum and Plasmodium vivax resistance to available
anti-malarial drugs represents a major drawback in the control of malaria and its associated morbidity and mortality.
The aim of this study was to evaluate the chemoresistance profile of P. falciparum and P. vivax to commonly used
anti-plasmodial drugs in a malaria-endemic area in the Brazilian Amazon.
Methods: The study was carried out in Manaus (Amazonas state), in the Brazilian Amazon. A total of 88 P.
falciparum and 178 P. vivax isolates was collected from 2004 to 2007. The sensitivity of P. falciparum isolates was
determined to chloroquine, quinine, mefloquine and artesunate and the sensitivity of P. vivax isolates was
determined to chloroquine and mefloquine, by using the colorimetric DELI test.
Results: As expected, a high prevalence of P. falciparum isolates resistant to chloroquine (78.1%) was observed. The
prevalence of isolates with profile of resistance or decreased sensitivity for quinine, mefloquine and artesunate was
12.7, 21.2 and 11.7%, respectively. In the case of P. vivax, the prevalence of isolates with profile of resistance for
chloroquine and mefloquine was 9.8 and 28%, respectively. No differences in the frequencies of isolates with profile
of resistance or geometric mean IC50s were seen when comparing the data obtained in 2004, 2005, 2006 and
2007, for all tested anti-malarials.
Conclusions: The great majority of P. falciparum isolates in the Brazilian malaria-endemic area remain resistant to
chloroquine, and the decreased sensitivity to quinine, mefloquine and artesunate observed in 10–20% of the
isolates must be taken with concern, especially for artesunate. Plasmodium vivax isolates also showed a significant
proportion of isolates with decreased sensitivity to chloroquine (first-line drug) and mainly to mefloquine. The data
presented here also confirm the usefulness of the DELI test to generate results able to impact on public health
policies.
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Malaria is one of the most serious public health problems
worldwide. It is a leading cause of disease and death in
many developing countries, where young children and
pregnant women are the most affected groups. Malaria is
endemic in 99 countries and, according to the World
Health Organization (WHO), there were about 219 million
cases of malaria and an estimated 660,000 malaria deaths
in 2010 [1].
In Brazil, malaria is hypo- to meso-endemic, present
throughout the year with clear seasonal fluctuations
and is frequently associated with migration movements
of non-immune individuals to areas where malaria is
endemic [2]. In 2011, approximately 263,000 malaria cases
were reported in Brazil, 99.8% of them in the Amazon
Region [3].
In the absence of an effective vaccine, malaria control is
almost entirely dependent on the availability of effective
chemotherapy and the efficacy of anti-vectorial measures.
The emergence and spread of Plasmodium falciparum
resistance to anti-malarial drugs thus represent a major
drawback in the control of malaria and its associated
morbidity and mortality. Resistance to current available
anti-malarial drugs has been reported in many places in
the world, including Brazil. The case of chloroquine is
representative. Chloroquine appeared in the 1940s as an
extraordinary anti-malarial drug: effective, cheap and easy
to produce. However, since the first reports of P. falciparum
parasites with reduced sensitivity to chloroquine [4-7], the
resistance to this drug spread rapidly throughout the world.
In many places, it became no longer effective and had to
be substituted by other drugs, more expensive and in
many cases presenting considerable side effects. The same
was true in Brazil, where the first report of P. falciparum
resistance to chloroquine was in the 1960s [4] and, by
1990, more than 95% of P. falciparum isolates circulating
in malaria endemic areas were resistant to chloroquine [8].
Given the strong impact of chemoresistance to anti-
malarial drugs in the control of malaria, monitoring
the development of resistant phenotypes is a priority
wherever malaria is endemic. The in vitro methods for
evaluating anti-malarial drug sensitivity can provide a
profile of plasmodial sensitivity to a variety of drugs, since
several drugs can be assayed simultaneously. A lower
sensitivity in vitro of an isolate does not necessarily
mean that it will be resistant in vivo, because the in vivo
outcome depends on a number of factors that cannot be
evaluated in vitro. However, it can provide an outline of
resistant phenotypes circulating for each drug tested when
using samples from an adequate number of patients in a
given area, thus providing crucial information for policy-
makers to determine the best drug to be employed in the
area. Ideally, monitoring of antimalarial chemoresistance
must be continuous, since development and spread ofresistance are dynamic events, changing with time and
according to human interventions and other factors, such
as population migration.
A good alternative for microscopic and isotopic in vitro
methods appeared with the development of immuno-
enzymatic methods to evaluate plasmodial growth. The
double-site enzyme-linked immunodetection (DELI) test
[9,10] is based on the detection of the parasite lactate
dehydrogenase (LDH), produced during the plasmodial
growth, by means of monoclonal antibodies, in a sandwich
ELISA. Deli-test assay proved to be reproducible, very
sensitive to detect low parasitaemia (0.005%) and easy
to perform even in field conditions, and without the need
of well training microscopists or manipulation of [3] hypo-
xanthine [10-13]. As an ELISA procedure, it allows the fast
evaluation of many samples at once. In addition, DELI-test
is easier to perform, faster to implement, and cheaper
than in vitro isotopic assays [10]. With the development
of an efficient short-term culture protocol for in vitro
Plasmodium vivax culture [14], and the availability of
monoclonal antibodies specific for P.vivax LDH, DELI
test also allows the study of the sensitivity of this parasite
to anti-malarial drugs.
The aim of this study was to evaluate the chemoresistance
profile of P. falciparum and P. vivax to commonly used
anti-plasmodial drugs in a Brazilian malaria-endemic area
in the Amazon Region using the DELI-test.
Methods
Studied area and isolates
This study was carried out in the city of Manaus (Amazonas
state), located at the Brazilian Amazon. A total of 88 P.
falciparum and 178 P. vivax isolates were collected
from patients who sought health care at Dr Heitor Vieira
Dourado Tropical Medicine Foundation (FMT-HVD) from
2004 to 2007.
Written informed consent was obtained from all donors
and venous blood samples were drawn in Vacutainer®
(Becton Dickinson, Oxnard, CA) EDTA tubes. Thin and
thick blood smears were examined for identification of
malaria parasite and determination of parasitaemia by two
expert malaria microscopists from FMT-HVD and from
the Laboratory of Malaria Research (Fiocruz, Rio de Janeiro,
Brazil) which is a reference centre in malaria diagnosis for
the Brazilian Ministry of Health. Thick blood smears from
all subjects were stained with Giemsa and examined under
1,000-fold magnification. Parasitaemia was determined by
counting parasites in reference to 200 white blood cells in
thick blood films, and the number of the blood parasites
per millilitre was calculated.
All malaria patients enrolled in this study complied
with the following criteria: 1) they presented symptoms; 2)
they had P. falciparum or P. vivax infection; 3) they
neither used chemoprophylaxis nor took anti-malarial
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5) females were not pregnant or breast feeding; and, 6)
blood collection was performed at the day of diagnosis
before malaria treatment. After malaria diagnosis and blood
sample collection, the patients were immediately treated
according to the Brazilian Ministry of Health standards
for malaria therapy.
The study was reviewed and approved by the Fundação
Oswaldo Cruz Ethical Committee (number 221/03).
Drug sensitivity assay
The sensitivity of P. falciparum isolates was determined to
chloroquine sulphate, quinine hydrochloride, mefloquine
hydrochloride, and artesunate and the sensitivity of P.
vivax isolates was determined to chloroquine sulphate
and mefloquine hydrochloride (all drugs obtained from
Sigma-Aldrich).
Anti-malarial drugs aliquoted in predosed tubes
(15 mg/tube) were dissolved by the addition of 3 mL of
100% ethanol and 7 mL of RPMI-1640 medium (Gibco,
Invitrogen Life Technologies) (chloroquine and quinine)
or 10 mL of 100% methanol (mefloquine and artesunate).
From the stock solution, another solution was prepared
for each drug at final concentrations of 2,400 ng/mL for
chloroquine, 1,200 ng/mL for quinine and 150 ng/mL
for mefloquine and artesunate in RPMI-1640 medium
supplemented with 0.5% albumax (Gibco) (complete cul-
ture medium), for P. falciparum; and 600 ng/mL for
chloroquine and 300 ng/mL for mefloquine in a 3:1 mix
(vol/vol) of RPMI 1640 medium and Waymouth medium
(Sigma-Aldrich), for P. vivax. One hundred mL of each
dilution were added to wells of the column 1 of 96-well
tissue culture plates (Falcon) and nine subsequent two-fold
dilutions were prepared in wells 2–9. Wells 10–12 were
filled with 50 μL of complete culture medium (culture con-
trol wells). Each concentration of anti-malarial was tested
in duplicate (P. falciparum) or quadruplicate (P. vivax).
Isolates with at least 0.1% parasitaemia were included
in the study and were maintained at 4°C (for up to 8 hr
after collection) before the in vitro culture was started.
Blood samples were washed twice with a solution of
RPMI-1640 medium and then resuspended in the
complete culture medium (P. falciparum) or RPMI-
Waymouth (P. vivax). If necessary, a dilution was performed
by adding uninfected O-positive-group erythrocytes to
obtain a 0.5–1% parasite density. Finally, 200 μL of this
suspension were distributed to each well in the anti-Table 1 Frequencies of Plasmodium falciparum and Plasmodiu
Brazil, with IC50 of commonly used anti-malarial drugs deter
2004 nd/n (%) 2005 nd/n (%)
P. falciparum 16/30 (53) 18/19 (94)
P. vivax 11/23 (48) 24/44 (55)
nd: number of samples with IC50 determined; n: number of total samples (percentamalarial predosed plates in 1.2% final haematocrit. The
plates were incubated for 48 hr at 37°C in a CO2 incubator
(5% CO2 in air) and were then frozen and kept at −20°C.
Before ELISA, the plates were frozen and thawed three
times to lyse the red blood cells.
ELISA
The success of the drug sensitivity assay and the appro-
priate volume of haemolysed culture were previously
determined for each clinical isolate by using a preliminary
LDH ELISA as a pretest. To determine which dilution of
haemolysed culture had to be used in the DELI-test, four
serial dilutions (1:50, 1:25, 1:12.5, 1:6.25) of culture control
wells (no drug) of each isolate were tested in a preliminary
LDH ELISA. The dilutions used were those providing
optical density (OD) readings between 1.0–2.0.
ELISA plate (Nunc, Maxisorb, Denmark) wells were
coated with 100 μL of monoclonal antibody (MAb) against
P. falciparum (17EA) or P. vivax (11D) LDH (kind gifts
of Dr Michael Makler, Flow Inc, Portland, USA) at 1
μg/mL, in PBS pH 7.4. The plates were incubated over-
night at 4°C, washed with PBS with 1% BSA (fraction V,
Boehringer-Mannheim) (PBS-BSA) and then incubated
with 300 μL of PBS-BSA for 4 hr, at room temperature.
The plates were maintained at 4°C until used.
Subsequently, the appropriated volume of the haemolysed
culture was transferred to the ELISA plate wells with
PBS-BSA to the final volume of 100 μL, incubated for
1 hr at 37°C and then washed with PBS-BSA. After the
addition of 100 μL per well of a biotinylated MAb against
pan-Plasmodium LDH (19G7), the plates were incubated
for 1 hr at 37°C. After washing, a third incubation for
30 min at room temperature with 100 μL of a streptavidin
horseradish peroxidase solution was followed by a last
washing step. Enzyme activity was revealed by incuba-
tion for 5 min at room temperature with 100 μL of
tetramethylbenzidine (TMB). The reaction was stopped
with 1 M of phosphoric acid, and the absorbance was read
at 450 nm in a spectrophotometer (Spectramax 250,
Molecular Devices).
Concentration-response data were analysed by a non-
linear regression function to determine the 50% inhibition
of parasite growth (IC50), defined as the concentration of
the drug which inhibited 50% of the production of LDH
as determined by OD values from sample test wells
compared to those obtained from drug-free control wells.
The IC50 threshold values for resistance to chloroquine,m vivax field isolates from Manaus, Amazonas State,
mined in 2004, 2005, 2006 and 2007
2006 nd/n (%) 2007 nd/n (%) Total nd/n (%)
20/22 (91) 16/17 (94) 70/88 (80)
32/38(84) 65/73(89) 132/178 (74)
ge).
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500 nM and 10 nM, respectively; these values were similar
to those already described elsewhere [10,11,15,16].
Statistical analysis
The data were stored in the Fox-plus® (Borland Inter-
national Inc, Perrysburg, OH, USA) data bank software.
GraphPad Instat and GraphPad Prism (GraphPad Software
Inc, CA, USA) statistical software programs were used for
data analysis. The Student’s t-test was used to analyse the
differences in IC50 mean values and the Chi-square testP. falciparum  Dd2 strain
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Figure 1 Example of curves for Plasmodium falciparum and Plasmodiu
chloroquine-sensitive 3D7 strain (B), isolate from one patient with P. falciparum
(D) cultures in presence of chloroquine, quinine, mefloquine and artesunate (was applied to compare the prevalence of isolates with
profile of resistance observed from 2004 to 2007.Results
A total of 88 P. falciparum and 178 P. vivax samples was
collected from malaria patients from 2004 to 2007. Males
were predominant in both P. falciparum (71%) and P.
vivax (81%) groups. The average age was also similar
between P. falciparum (36 ± 15 years old) and P. vivax
(34 ± 13 years old) groups.P. falciparum  3D7 strain
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m vivax. P. falciparum chloroquine-resistant Dd2 strain (A), P. falciparum
infection (C) and isolate from one patient with P. vivax infection
P. falciparum) or chloroquine and mefloquine (P. vivax).
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Figure 2 Distribution of IC50 values in Plasmodium falciparum and Plasmodium vivax isolates using DELI test. Plasmodium falciparum
isolates (A), Plasmodium vivax isolates (B). Values are individual IC50 (nM). Lines represent geometric mean with 95% confidence interval.
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P. falciparum (70/88, 80%) and P. vivax (132/178, 74%)
samples (Table 1). Successful in vitro culture allowing
IC50 determination for fresh isolates was low in the
first year (2004) for both P. falciparum and P. vivax cul-
tures, but substantially increased in the subsequent years,
suggesting better handling and optimization of culture
procedures (Table 1). The feasibility of the procedure
using chloroquine-sensitive (Dd2) and chloroquine-resistant
(3D7) strains adapted for in vitro culture was determined
and showed that it worked well (Figure 1).
As expected, a high prevalence of P. falciparum isolates
resistant or with decreased susceptibility to chloroquine
was observed (Figure 2A). Indeed, 78.1% (50/64) of the
samples showed IC50 higher than 100 nM. The geometric
mean IC50s for chloroquine was 361.8 nM (95% confidence
interval 266–492 nM) (Table 2). For quinine, the prevalence
of clearly resistant isolates (IC50 > 500 nM) was 12.7%
(8/63). The geometric mean IC50s for quinine was 128.5
nM (95% confidence interval 93–175). For mefloquine,
the prevalence of isolates with profile of resistance or
decreased susceptibility (IC50 > 30nM) was 21.2% (14/66).
The geometric mean IC50s for mefloquine was 14.2 nM
(95% confidence interval 10–20). Finally, for artesunate,
the prevalence of isolates with IC50 above the threshold
of 10 nM was 11.7% (6/51). The geometric mean of IC50s
was 3.4 nM (95% confidence interval 3–4). No difference
in frequencies of isolates with profile of resistance or
geometric mean IC50s were seen comparing the data
obtained in 2004, 2005, 2006 and 2007 for chloroquine,
quinine, mefloquine and artesunate.
Among P. falciparum isolates, different chloroquine,
quinine, mefloquine, and artesunate sensitivity levels were
observed, however, the temporal analysis indicate that the
profile of sensitivity to these drugs remained relatively
stable.
In the case of P. vivax isolates, the prevalence of isolates
with IC50 above threshold of 100 nM for chloroquine was
9.8% (13/132) (Figure 2B) and the geometric mean
IC50 was 24.1 nM (95% confidence interval 20–29).
For mefloquine, the prevalence of IC50 above threshold of
30 nM was 28% (22/78) and the geometric mean IC50Table 2 IC50 values of commonly used anti-malarial drugs in
Plasmodium vivax from Manaus, Amazonas State, Brazil
P. falciparum
IC50 (nM)
Drug1 No. of isolates Geometric mean 95% CI2 Ra
Chloroquine 64 361.8 266–492 9–3
Quinine1 63 128.5 93–175 12–
Mefloquine 66 14.2 10–20 2–7
Artesunate1 51 3.4 3–4 0.3
1Performed only in P. falciparum cultures; 2CI, confidence interval.was 18.1 nM (95% confidence interval 14–23) (Table 2).
No difference in frequencies of isolates with profile of
resistance or geometric mean IC50s were seen comparing
the data obtained in 2004, 2005, 2006 and 2007 for chloro-
quine and mefloquine.Discussion
In the present study, the DELI-test was used to determine
the profile of in vitro sensitivity of P. falciparum and P.
vivax field isolates in Manaus, in the Brazilian Amazon.
Despite some initial technical difficulties in the beginning
of the study (2004), the performance of the test in
2005–2007 was similar to that observed in previous studies
in Africa, which reported test success rates of 81% for
P. falciparum [13].
Overall, a high prevalence (78.1%) of P. falciparum
isolates resistant or with decreased sensitivity to chloro-
quine was observed. This was expected since earlier studies
conducted in Amazonia suggested that 100% of the P.
falciparum isolates circulating in the area were chloroquine-
resistant [17]. In addition, most of the “sensitive” iso-
lates had IC50s close to the threshold for sensitivity
(100 nM) and therefore represent rather borderline isolates.
Only 2/64 (3.1%) of isolates showed clearly low IC50
to chloroquine. Any evidence of the re-emergence of
chloroquine-sensitive parasites in Brazil through the
documentation of a wild pfcrt P. falciparum haplotype
(CVMNK) in Amazonian region was already reported [18].
In Brazil, reduced in vitro and in vivo sensitivity to
mefloquine has been reported since 1981 [19-23] and
this might explain the 21.2% resistant phenotypes in the
present study. In fact, even before the official introduction
of mefloquine in Brazilian endemic areas in 1987, P.
falciparum isolates with profile of resistance to mefloquine
had already been reported [24].
In relation to quinine, the prevalence of resistant isolates
(IC50 above 500 nM) was 12.7%. Some isolates showed
IC50s very close to the threshold. In any case, this
scenario is worrisome because a continuous decreasing in
parasite sensitivity has been noted in the Brazilian Amazon
[17,21,24-27] and quinine plus doxycycline is actuallyin vitro culture of Plasmodium falciparum and in
P. vivax
IC50 (nM)
nge No of isolates Geometric mean 95% CI2 Range
373 132 24.1 20–29 5–729
2174 - - - -
23 78 18.1 14–23 2–337
–52 - – – -
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the Brazilian Malaria Control Programme.
Since 2007 the Brazilian Malaria Control Programme
defined artemisinin-based combined therapy (ACT) as the
first-line treatment for uncomplicated falciparum malaria.
In this study, 11.7% of the isolates showed IC50 above the
threshold of 10 nM (11.7%) for artesunate. This is surpris-
ing as these samples were collected in a period before the
introduction of ACT in the area; therefore, no selection
pressure is to be accounted for. A study performed in
another area in the Amazonian region in the same
period, showed no evidence of decreased sensitivity of
local isolates to artesunate or artemether [28]. How-
ever, a recent study showed that 23.9% of the studied
isolates from Gabon had a reduced susceptibility to
dihydroartemisinin [16]. Decreased sensitivity of P. falcip-
arum parasites to artemether in vitro in French Guiana
and Senegal [29] as well as in vivo in Cambodia [30] has
also been described. Given the immense value of artemisi-
nin derivatives as alternative drugs for multidrug-resistant
parasites, authorities must be alert to these data indicating
a trend for emergence of isolates with decreased sensitivity
to this drug.
The sensitivity of P. vivax parasites to anti-malarial drugs
has not been widely monitored in vitro due the difficulties
in cultivating P. vivax. Here, the in vitro resistance of
P. vivax fresh isolates to chloroquine and mefloquine
was evaluated for the first time in Brazil. Although the
threshold of IC50 to define a sample as resistant to
chloroquine is not well established for P. vivax, it has been
proposed that the same threshold used for P. falciparum
should be used for P. vivax [15]. In this case, a consider-
able frequency (9.8%) of P. vivax isolates was above the
adopted 100 nM threshold of chloroquine. This frequency
was not surprising, because P. vivax resistance to chloro-
quine has been reported in Brazil [31,32], as well as
increasing numbers of severe P. vivax malaria cases
[33,34]. Consequently, the use of DELI test can be an im-
portant tool for backing decisions of the Brazilian health
authorities in relation to the treatment policy of P. vivax.
Mefloquine is usually an alternative treatment for P.
vivax infections. Interestingly, the prevalence of P.
vivax isolates with resistant profile to mefloquine was
greater (28%) than to P. falciparum parasites (21.2%),
corroborating a study performed in Thailand where P.
vivax isolates were more resistant to mefloquine when
compared with P. falciparum isolates from the same
area [35].
It should be highlighted that the in vivo outcome
depends on a number of factors that cannot be evaluated
in vitro, including the level of innate and acquired immun-
ity. However, in vitro assays act as a preliminary warning
system indicating a trend, since in vitro resistance may be
indicative of clinical resistance.Conclusions
The data here presented using DELI test provide important
and useful information regarding the sensitivity profile
of Brazilian plasmodial isolates to common anti-malarial
drugs. For updating and evaluating potential shifts in the
profiles of drug sensitivity, periodic such studies associated
with the screening using potential molecular markers
should be performed.
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